Novo Nordisk A/S – Finance Tailwind

Eli Lilly to build $5 billion Virginia manufacturing facility

CPI report health care inflation rises

Obesity pills from Eli Lilly, Novo Nordisk near US launch

Trump administration has backup plans for tariffs

Stoxx 600, FTSE, DAX, data

Eli Lilly weight loss pill orforglipron clears trial, paving way for approval

Eli Lilly’s obesity pill will rival Novo Nordisk’s oral Wegovy drug

European pharma secured a U.S. tariff win. Investors remain wary

FDA approves Signos glucose monitoring for weight loss

Viking Therapeutics falls 30% on drug data